tbuckley/cabot-search huggingface dataset:
Abstract 17685: Exploration for the Appropriate Timing of the Resuscitative Endovascular Balloon Occlusion of the Aorta for Severely Injured Trauma Patients
Authors: Shu Utsumi
Journal: Circulation (2017)

Background: The clinical efficacy of the resuscitative endovascular balloon of the Aorta (REBOA) for trauma has been controversial, and the complications related REBOA couldn’t be ignored. We hypot...
Efficacy of Systemic Therapies for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL): A Systematic Literature Review (SLR)
Authors: Emmanuel Bachy, Christopher P. Fox, Luca Arcaini, Francisco J. Hernandez-Ilizaliturri, Susannah Howlett, Sonya J. Snedecor, Jacob Franek, Omer Zaidi, Ashley Tabah
Journal: Blood (2018)
Abstract P077: Missed Opportunities for Behavioral Counseling by Primary Care Providers
Authors: John D Omura, Susan A Carlson, Prabasaj Paul, Kathleen B Watson, Fleetwood Loustalot, Janet E Fulton
Journal: Circulation (2016)

Background: In 2014, the US Preventive Services Task Force recommended adults who are overweight or obese and have additional cardiovascular disease (CVD) risk factors be offered or referred to intensive behavioral counseling interventions to promote a healthful diet and physical activity for CVD prevention. Hypothesis: We hypothesized that primary care providers (PCPs) who discussed physical activity with most of their at risk patients would have a higher prevalence of offering select components than PCPs who discussed physical activity less frequently. Methods: DocStyles 2015, a Web-based panel survey of 1251 PCPs (response rate=76.8%), assessed physical activity counseling practices with patients at risk for CVD (overweight or obese and with hypertension, dyslipidemia, impaired fasting glucose, or the metabolic syndrome). Results: Overall, 55.9% (SE=1.4) of PCPs discussed physical activity with most of their patients at risk for CVD. Among respondents who discussed physical activity with any at risk patients (N=1244), the prevalence of components offered when they counseled ranged from 92.6% encouraging increased physical activity to 15.8% referring to intensive behavioral counseling (Table). PCPs who discussed physical activity with most at risk patients had a higher prevalence of offering all counseling components assessed than PCPs who discussed physical activity less frequently, except for referring to intensive behavioral counseling where no difference was found. Of all PCPs, 8.4% both discussed physical activity with most of their at risk patients and referred them to intensive behavioral counseling. Conclusion: Just over half of PCPs surveyed discussed physical activity with most patients at risk for CVD. These PCPs more frequently offered select components when they counseled with the exception of referral to intensive behavioral counseling. Both the low levels of counseling and referral to intensive behavioral counseling present important opportunities for improving counseling practices.
Genome-Wide Screening and Functional Analysis Identifies Tumor Suppressor Long Noncoding RNAs Epigenetically Silenced in Hepatocellular Carcinoma
Authors: Feiyue Xu, Chi Han Li, Chi Hin Wong, George G. Chen, Paul Bo San Lai, Shengwen Shao, Stephen L. Chan, Yangchao Chen
Journal: Cancer Research (2019)

Long noncoding RNAs (lncRNA) play critical roles in the development of cancer, including hepatocellular carcinoma (HCC). However, the mechanisms underlying their deregulation remain largely unexplored. In this study, we report that two lncRNAs frequently downregulated in HCC function as tumor suppressors and are epigenetically silenced by histone methyltransferase EZH2. lncRNAs TCAM1P-004 and RP11-598D14.1 were inhibited by EZH-mediated trimethylation of H3K27me3 at their promoters. Downregulation of TCAM1P-004 and RP11-598D14.1 was frequently observed in HCC tumors compared with adjacent normal tissues. Both lncRNAs inhibited cell growth, cell survival, and transformation in HCC cells in vitro as well as tumor formation in vivo. Using RNA pull-down and mass spectrometry, we demonstrated that TCAM1P-004 bound IGF2BP1 and HIST1H1C, whereas RP11-598D14.1 bound IGF2BP1 and STAU1. These lncRNA-protein interactions were critical in regulating p53, MAPK, and HIF1α pathways that promoted cell proliferation in HCC. Overexpression of EZH2 was critical in repressing TCAM1P-004 and RP11-598D14.1, and EZH2-TCAM1P-004/RP11-598D14.1-regulated pathways were prevalent in human HCC. Aberrant suppression of TCAM1P-004 and RP11-598D14.1 led to loss of their tumor-suppressive effects by disrupting the interaction with IGF2BP1, HIST1H1C, and STAU1, which in turn promoted HCC development and progression. Collectively, these findings demonstrate the role of TCAMP1P-004 and RP11-598D14.1 in suppressing tumor growth and suggest that EZH2 may serve as a therapeutic target in HCC. SIGNIFICANCE: EZH2-mediated loss of lncRNAs TCAM1P-004 and RP11-598D14.1 hinders the formation of tumor suppressor lncRNA-protein complexes and subsequently promotes HCC growth.
Experimental Bacterial Endocarditis Due to Streptococcus Mitis
Authors: ROBERT A. RABENS, JOSEPH E. GERACI, JOHN H. GRINDLAY, ALFRED G. KARLSON
Journal: Circulation (1955)

It is important in order to advance the increasingly successful attack on subacute bacterial endocarditis to be able to produce the disease experimentally and to treat it with new and improved therapeutic regimens. Since endocarditis caused by Streptococcus mitis has not been consistently produced previously in the dog, a study was undertaken in which cardiovascular stress was created by the establishment of aortico-inferior vena caval and bilateral iliofemoral arteriovenous shunts. After a period of antibacterial treatment and of stabilization, daily intravenous injections of broth cultures of S. mitis were begun. In 50 per cent of 24 animals bacterial endocarditis developed,simulating that found in clinical cases at necropsy. These animals had widely patent fistulas and 11 showed evidences of congestive heart failure. Of the remaining 12 animals, five with patent fistulas died of the effects of multiple infected pulmonary emboli. Seven others whose shunts had closed were killed and found to have no significant lesions other than healed caval infections.
Brexit: GPs are told to resist patients’ requests to overprescribe
Authors: Gareth Iacobucci
Journal: BMJ (2019)

GPs should resist requests from patients to issue longer repeat prescriptions in the run up to Brexit and should liaise closely with pharmacists if they are concerned about shortages of specific drugs, experts have advised.

The Department of Health and Social Care for England has told GPs not to stockpile drugs or overprescribe in response to Brexit and has insisted that contingency plans will ensure continuity of supply even if the UK leaves the European Union on 29 March without a deal.

But with no deal still a distinct possibility, GPs are reporting that some patients are concerned about the supply of their drugs.

Krishna Kasaraneni, executive member of the BMA’s General Practitioners Committee, said, “Some patients are asking for greater quantities of their medicines because they are concerned about potential shortages due to Brexit. One …
Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Test—In Reply
Authors: Pascal Bamford, Ryan Dittamore, Howard I. Scher
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
Authors: James Chih-Hsin Yang, Frances A. Shepherd, Dong-Wan Kim, Gyeong-Won Lee, Jong Seok Lee, Gee-Chen Chang, Sung Sook Lee, Yu-Feng Wei, Yun Gyoo Lee, Gianluca Laus, Barbara Collins, Francesca Pisetzky, Leora Horn
Journal: Journal of Thoracic Oncology (2019)

IntroductionOsimertinib is a third-generation EGFR-tyrosine kinase inhibitor (TKI). Durvalumab is an anti–programmed death ligand 1 monoclonal antibody. The phase III open-label CAURAL trial (NCT02454933) investigated osimertinib plus durvalumab versus osimertinib monotherapy in patients with EGFR-TKI sensitizing and EGFR T790M mutation–positive advanced NSCLC and disease progression after EGFR-TKI therapy.MethodsPatients were randomly assigned 1:1 to receive orally administered osimertinib (80 mg once daily) with or without durvalumab (10 mg/kg administered intravenously every 2 weeks) until progression. Treatment could continue beyond progression, providing clinical benefit continued (judged by the investigator). The amended primary objective was to assess the safety and tolerability of osimertinib plus durvalumab; efficacy was an exploratory objective.ResultsCAURAL recruitment was terminated early because of increased incidence of interstitial lung disease–like events in the osimertinib plus durvalumab arm from the separate phase Ib TATTON trial (NCT02143466). At termination of CAURAL recruitment, 15 patients had been randomly assigned to treatment with osimertinib and 14 to treatment with osimertinib plus durvalumab. The most common AEs were diarrhea (53% [grade ≥3 in 6% of patients]) in the osimertinib arm and rash (67% [grade ≥3 in 0 patients]) in the combination arm. One patient who had been randomized to the combination arm reported grade 2 interstitial lung disease while receiving osimertinib monotherapy (after discontinuing durvalumab therapy after one dose). The objective response rates were 80% in the osimertinib arm and 64% in the combination arm.ConclusionLimited patient numbers preclude formal safety and efficacy comparisons between the two treatment arms. The combination of programmed cell death 1/programmed death ligand 1 inhibitors and EGFR-TKIs as therapy for NSCLC is not well understood, but it requires a careful approach if considered in the future.
Bone Marrow Stromal Cells Mediate Adhesion Based Drug Resistance in Acute Myeloid Leukaemia through Reciprocal Feedback of the β-Catenin/CD44 Signalling Axis
Authors: Lihui Zhuang, Richard Darley, Oliver G. Ottmann, Joanna Zabkiewicz, Caroline Alvares
Journal: Blood (2018)
Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3).
Authors: Markus Hermann Moehler, Gunnar Folprecht, Volker Heinemann, Julian Holch, Annett Maderer, Stefan Kasper, Susanna Hegewisch-Becker, Jan Schroeder, Friedrich Overkamp, Frank Kullmann, Wolf Otto Bechstein, Matthias Vöhringer, Robert Oellinger, Florian Lordick, Michael Geissler, Armin Schulz-Abelius, Bernhard Linz, Helga Bernhard, Irene Schmidtmann, Carl Christoph Schimanski
Journal: Journal of Clinical Oncology (2019)

571 Background: Metastatic colorectal cancer (mCRC) patients (pts) with liver-limited disease (LLD) have a chance of long-term overall survival (OS) and potential cure after complete hepatic metastasectomy. The appropriate postoperative treatment strategy is still controversial. L-BLP25 as antigen-specific cancer vaccine targeting mucin 1 (MUC1) was recently evaluated as adjuvant therapy in mCRC pts after R0/R1 LLD resection (LICC trial, NCT01462513). Here we compared the LICC surveillance program and efficacy results for secondarily resected LLD pts versus historical controls, i.e. the CELIM trial (Folprecht et al, Ann Oncol 2014) of potentially resectable LLD mCRC pts and a FIRE-3-LLD subgroup (Holch et al, Int J Cancer 2018). Methods: LICC, CELIM and FIRE-3-LLD subgroup pts with stage IV mCRC limited to liver metastases who underwent hepatic resection (R0 or R1) were compared regarding pts characteristics, surveillance and efficacy outcome. LICC pts received adjuvant L-BLP25 or placebo after secondary LLD resection as 8 weekly doses, followed by 6 week maintenance intervals and tight surveillance until recurrence or a maximum of 2 years. Results: In LICC, 41/121 pts (33.9%) were secondarily resected, and R0 resection was achieved in 31 pts (75.6%). In CELIM, 36/106 pts (34%) with primary unresectable LLD were secondarily R0 resected. In FIRE-3-LLD, secondary resection was feasible for 29/133 pts (21.8%). After R0 resection, median recurrence free survival (mRFS) was 8.9 months in LICC, 9.9 months in CELIM and 11.5/12.4 months in FIRE-3-LLD in either treatment arm. In the LICC trial, median overall survival (mOS) in secondarily resected pts was 65.1 months, with 38.3 months for the R1 and is not yet reached for the R0 subgroup. In CELIM, mOS was 53.9 months for R0 resected pts. In FIRE-3-LLD, after secondary resection mOS was 56.2 months. Median age was about 5 years less in LICC. Further details will be presented. Conclusions: Secondary resected pts of LICC, CELIM and FIRE-3 showed impressive median OS with better OS for LICC and a younger patient cohort. The established tight LICC surveillance program after surgery might have had a positive impact on survival. Clinical trial information: LICC: NCT01462513; FIRE-3: NCT00433927; CELIM: NCT00153998.
Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial
Authors: S. Delaloge, D. Cella, Y. Ye, M. Buyse, A. Chan, C.H. Barrios, F.A. Holmes, J. Mansi, H. Iwata, B. Ejlertsen, B. Moy, S.K.L. Chia, M. Gnant, S. Smichkoska, A. Ciceniene, N. Martinez, S. Filipović, N.E. Ben-Baruch, A.A. Joy, S.T. Langkjer, F. Senecal, R.H. de Boer, S. Moran, B. Yao, R. Bryce, A. Auerbach, L. Fallowfield, M. Martin
Journal: Annals of Oncology (2019)

We report longitudinal health-related quality-of-life (HRQoL) data from the international, randomized, double-blind, placebo-controlled phase III ExteNET study, which demonstrated an invasive disease-free survival benefit of extended adjuvant therapy with neratinib over placebo in human epidermal growth factor receptor-2-positive early-stage breast cancer.
Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy — a Study By the Lysa Group
Authors: Yannick LE Bris, Olivier Theisen, Anne Moreau, Florence Magrangeas, Danielle Canioni, Barbara Burroni, Catherine Thieblemont, Lucie Oberic, Krimo Bouabdallah, Emmanuel Gyan, David Chiron, Catherine Pellat-deceunynck, Benoit Tessoulin, Catherine Godon, Marie-Helene Delfau, Mary Callanan, Stephane Minvielle, Marie C Bene, Olivier Hermine, Steven LE Gouill
Journal: Blood (2018)
Gene Therapy for Sickle Cell Disease Shows Promise
Authors: Rita Rubin
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Self-compression Technique vs Standard Compression in Mammography
Authors: Philippe Henrot, Martine Boisserie-Lacroix, Véronique Boute, Philippe Troufléau, Bruno Boyer, Grégory Lesanne, Véronique Gillon, Emmanuel Desandes, Edith Netter, Maryam Saadate, Anne Tardivon, Christine Grentzinger, Julia Salleron, Guillaume Oldrini
Journal: JAMA Internal Medicine (2019)

Many women dread undergoing mammography, and some may not attend or reattend breast cancer screening because of the discomfort or pain induced by breast compression.To evaluate the noninferiority of the self-compression mammography technique for reducing breast thickness compared with standard compression.This prospective, parallel-group, noninferiority randomized clinical trial was conducted from May 7, 2013, to October 26, 2015, at 6 cancer care centers in France. Participants were women aged 50 to 75 years, without a history of recent breast surgical procedure or treatment, and who could perform self-compression. Analyses were performed on intention-to-treat basis from January 27, 2017, to March 30, 2018.Patients were randomized 1:1 to the self-compression group or the standard compression group.Primary end point was breast thickness expressed as the mean of 4 views: right and left craniocaudal and right and left mediolateral oblique. The predefined noninferiority margin was a difference of 3 mm, with a 1-sided 95% CI. Secondary end points included compression force, image quality, requirement for additional views, pain, and patient satisfaction and radiographer assessment questionnaires.Among the 549 women randomized, 548 (97.3%) completed the trial. Of these, 275 (48.8%) (mean [SD] age, 61.35 [6.34] years) were randomized to the self-compression arm and 273 (48.5%) (mean [SD] age, 60.84 [6.41] years) to the standard compression arm. The difference in the mean thickness between the 2 arms was lower than the noninferiority margin, with an upper 1-sided 95% CI less than 3 mm (-0.17; 95% CI,-∞ to 1.89 mm; P < .05). Compression force was higher in the self-compression group compared with the standard compression arm for the 4 mammographic views. Pain was statistically significantly lower in the self-compression group (n = 274) compared with the standard compression group (n = 269) (median [interquartile range (IQR)] score, 2 [1-5] vs 3 [1-5]; P = .009). No difference was reported in the image quality scores of the 2 groups or in the number of additional views performed (median [IQR] extra views, 2 [2-2] vs 2 [2-3] extra views; P = .64), whatever the indication, including insufficient image quality (29 [16.8%] vs 27 [15.0%] insufficient quality views; P = .65). No adverse effects or pain were reported by the participants after the self-compression mammography.Self-compression does not appear to be inferior to standard compression mammography in achieving minimal breast thickness without increasing pain or compromising image quality; this technique may be an effective option for women who want to be involved in their breast examination.ClinicalTrials.gov identifier: NCT02866591.
Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline
Authors: Cesare Hassan, Piotr Wysocki, Lorenzo Fuccio, Thomas Seufferlein, Mário Dinis-Ribeiro, Catarina Brandão, Jaroslaw Regula, Leonardo Frazzoni, Maria Pellise, Sergio Alfieri, Evelien Dekker, Rodrigo Jover, Gerardo Rosati, Carlo Senore, Cristiano Spada, Ian Gralnek, Jean-Marc Dumonceau, Jeanin van Hooft, Eric van Cutsem, Thierry Ponchon
Journal: Endoscopy (2019)

Main Recommendations 1 We recommend post-surgery endoscopic surveillance for CRC patients after intent-to-cure surgery and appropriate oncological treatment for both local and distant disease.Strong recommendation, low quality evidence. 2 We recommend a high quality perioperative colonoscopy before surgery for CRC or within 6 months following surgery.Strong recommendation, low quality evidence. 3 We recommend performing surveillance colonoscopy 1 year after CRC surgery.Strong recommendation, moderate quality evidence. 4 We do not recommend an intensive endoscopic surveillance strategy, e. g. annual colonoscopy, because of a lack of proven benefit.Strong recommendation, moderate quality evidence. 5 After the first surveillance colonoscopy following CRC surgery, we suggest the second colonoscopy should be performed 3 years later, and the third 5 years after the second. If additional high risk neoplastic lesions are detected, subsequent surveillance examinations at shorter intervals may be considered.Weak recommendation, low quality evidence. 6 After the initial surveillance colonoscopy, we suggest halting post-surgery endoscopic surveillance at the age of 80 years, or earlier if life-expectancy is thought to be limited by comorbidities.Weak recommendation, low quality evidence. 7 In patients with a low risk pT1 CRC treated by endoscopy with an R0 resection, we suggest the same endoscopic surveillance schedule as for any CRC.Weak recommendation, low quality evidence.
Deaths Due to Thrombotic Versus Bleeding Events within 90 Days of Cancer Associated Thrombosis
Authors: Mailey L Wilks, Shyam K. Poudel, Deborah Y. Park, Xuefei Jia, Vicki Pinkava, Meghan O'Brien, Barb Tripp, Jung-Min Song, Keith R. McCrae, Alok A. Khorana, Dana E. Angelini
Journal: Blood (2018)
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study
Authors: Martin R Gaudinski, Emily E Coates, Laura Novik, Alicia Widge, Katherine V Houser, Eugeania Burch, LaSonji A Holman, Ingelise J Gordon, Grace L Chen, Cristina Carter, Martha Nason, Sandra Sitar, Galina Yamshchikov, Nina Berkowitz, Charla Andrews, Sandra Vazquez, Carolyn Laurencot, John Misasi, Frank Arnold, Kevin Carlton, Heather Lawlor, Jason Gall, Robert T Bailer, Adrian McDermott, Edmund Capparelli, Richard A Koup, John R Mascola, Barney S Graham, Nancy J Sullivan, Julie E Ledgerwood, Cynthia Starr Hendel, Sarah H. Plummer, Pamela Costner, Jamie Saunders, Floreliz Mendoza, Aba Mensima Eshun, Joseph Casazza, Abidemi Ola, William Whalen, Xiaolin Wang, Jennifer Cunningham, Olga Vasilenko, Catina R. Boyd, Olga Trofymenko, Maria Claudia Burgos Florez, Somia Hickman, Ro Shauna Rothwell, Iris R Pittman, Lam Ngan Le, Brenda D Larkin, Josephine H Cox, Preeti J Apte, Renunda T Hicks, Cora Trelles Cartagena, Pernell V Williams, LaShawn Requilman, Thuy Nguyen, Colin Tran, Sandra Vazquez, Michelle Conan-Cibotti, Judy Stein, Tatiana Beresnev
Journal: The Lancet (2019)
Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood
Authors: Gabriella Gobbi, Tobias Atkin, Tomasz Zytynski, Shouao Wang, Sorayya Askari, Jill Boruff, Mark Ware, Naomi Marmorstein, Andrea Cipriani, Nandini Dendukuri, Nancy Mayo
Journal: JAMA Psychiatry (2019)

Cannabis is the most commonly used drug of abuse by adolescents in the world. While the impact of adolescent cannabis use on the development of psychosis has been investigated in depth, little is known about the impact of cannabis use on mood and suicidality in young adulthood.